CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 100 enrolled
Drug / intervention
Orlistat +2 moredrug
Likely dose
Orlistat 60mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03582722
NCT03582722Phase 4Completed
CompareCT.gov

Use of a Weight Loss Aid in a Population Exposed to Polybrominated Biphenyls (PBB)

Emory University·interventional·Posted Jul 11, 2018·Updated Apr 25, 2024

In Brief

A Phase 4 clinical trial evaluating Orlistat, Placebo capsule, and 1 other intervention for Polybrominated Biphenyl Poisoning. Completed, enrolled 100 participants across 1 site.

Detailed Summary

This study will explore whether the use of orlistat results in weight loss that is accompanied by a reduction in the body burdens of polybrominated biphenyls (PBB) and other Persistent Organic Pollutants (POPs).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolybrominated Biphenyl Poisoning
CountriesUnited States
CollaboratorsHealthway Compounding Pharmacy, Michigan Public Health Departments, National Institute of Environmental Health Sciences (NIEHS)

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedJul 11, 2018
Enrollment StartSep 14, 2018
Primary CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 8.0 years ago

Interventions

Orlistatdrug

Participants will be instructed to take one 60mg capsule of orlistat with each meal containing fat, up to three capsules daily, for six months.

Placebo capsuledrug

Participants will be instructed to take one placebo capsule to match 60mg of orlistat with each meal containing fat, up to three capsules daily, for six months.

Multivitamindietary

A multivitamin will be provided to be taken once daily, at bedtime.